The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.

Blood Adv · 2022 · PMC8864654 · PMID 34933330

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Idasanutlin treatment showed a trend toward improvement in patient-reported outcomes, with a ≥50% reduction in symptom burden per MPN-SAF TSS experienced by 43% of patients at week 32.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.